Trial Profile
Ibrutinib Monotherapy in Early Stage Chronic Lymphocytic Leukemia (CLL) Without IWCLL/NCI-WG 2008 Treatment Indications But With High-Risk Features for Disease Progression
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 19 Jul 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2025.
- 19 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2025.
- 20 Jan 2023 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.